Funding for this research was provided by:
F. Hoffmann-La Roche
Received: 30 November 2017
Revised: 24 January 2018
Accepted: 29 January 2018
First Online: 5 March 2018
Change Date: 10 April 2018
Change Type: Correction
Change Details: The article “Progressive multifocal leukoencephalopathy in rituximab-treated rheumatic diseases: a rare event,” written by Joseph R. Berger, Vineeta Malik, Stuart Lacey, Paul Brunetta, and Patricia B. LehaneSuperscript removed, was originally published electronically on the publisher’s internet portal (currently SpringerLink).
Compliance with ethical standards
: All studies were previously reported and were in compliance with the Helsinki Declaration; local institutional review board approval was given at each participating site.
: Joseph R. Berger has received personal fees as a consultant to Genentech and Roche. He reports grants from Biogen, during the conduct of the study; personal fees from Amgen; personal fees from Astra-Zeneca; personal fees from Janssen; personal fees from Millennium/Takeda; personal fees from Novartis; personal fees from Biogen; personal fees from Genzyme/Sanofi; personal fees from Inhibikase; personal fees from Forward Pharma; personal fees from Johnson and Johnson; personal fees from Pfizer; and personal fees from Eisai, outside the submitted work.Vineeta Malik was an employee of Roche at the time of this study.Stuart Lacey is an employee of Roche.Paul Brunetta was an employee of Genentech at the time of this study.Patricia Lehane is an employee of Roche.